A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]
作者： Eduardo Collantes , , Sean P Curtis , Ka Wing Lee , Noemi Casas
关键词:
摘要: Background Etoricoxib is a highly selective COX-2 inhibitor which was evaluated for the treatment of rheumatoid arthritis (RA).
biomedcentral.com
springer.com
paperity.org参考文章(18)
Jerry M. Greene, Dorothy A. Johnson, Larry G. Anderson, Robert A. Yood, Robert W. Simms, Guidelines for the Management of Rheumatoid Arthritis ,(2002)
Harris H. McIlwain, Barry J. Gertz, David G. Borenstein, Christopher R. Lines, Sean Curtis, Peng Liang Zhao, David R. Mandel, Augustin Melian, Alan K. Matsumoto, A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. The Journal of Rheumatology. ,vol. 29, pp. 1623- 1630 ,(2002)
Thomas J Schnitzer, Ken Truitt, Roy Fleischmann, Paul Dalgin, Joel Block, Qi Zeng, James Bolognese, Beth Seidenberg, Elliot W Ehrich, Phase II Rofecoxib Rheumatoid Arthritis Study Group, The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis Clinical Therapeutics. ,vol. 21, pp. 1688- 1702 ,(1999) , 10.1016/S0149-2918(99)80048-4
Francesca Catella-Lawson, Leslie J Crofford, Cyclooxygenase inhibition and thrombogenicity. The American Journal of Medicine. ,vol. 110, pp. 28- 32 ,(2001) , 10.1016/S0002-9343(00)00683-5
Michael J Langman, Dennis M Jensen, Douglas J Watson, Sean E Harper, Peng-Liang Zhao, Hui Quan, James A Bolognese, Thomas J Simon, Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. ,vol. 282, pp. 1929- 1933 ,(1999) , 10.1001/JAMA.282.20.1929
James F. Fries, Catherine A. Williams, Daniel A. Bloch, Beat A. Michel, Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models The American Journal of Medicine. ,vol. 91, pp. 213- 222 ,(1991) , 10.1016/0002-9343(91)90118-H
D. Craig Brater, Cynthia Harris, Jan S. Redfern, Barry J. Gertz, Renal Effects of COX-2-Selective Inhibitors American Journal of Nephrology. ,vol. 21, pp. 1- 15 ,(2001) , 10.1159/000046212
D Mukherjee, S.E Nissen, E.J Topol, Risk of cardiovascular events associated with selective COX-2 inhibitors☆ Acc Current Journal Review. ,vol. 11, pp. 15- ,(2002) , 10.1016/S1062-1458(01)00545-1
Hyon K. Choi, Peter Lamprecht, John L. Niles, Wolfgang L. Gross, Peter A. Merkel, Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis & Rheumatism. ,vol. 43, pp. 226- 231 ,(2000) , 10.1002/1529-0131(200001)43:1<226::AID-ANR27>3.0.CO;2-Q
Paul Emery, Henning Zeidler, Tore K Kvien, Mario Guslandi, Raphael Naudin, Helen Stead, Kenneth M Verburg, Peter C Isakson, Richard C Hubbard, G Steven Geis, Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. The Lancet. ,vol. 354, pp. 2106- 2111 ,(1999) , 10.1016/S0140-6736(99)02332-6